Related Experiment Video
Updated: Jan 18, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
16.2K
Current omics-based biomarkers for cholangiocarcinoma.
Kitti Intuyod1,2, Napat Armartmuntree2,3, Apinya Jusakul2,4
1Department of Parasitology, Faculty of Medicine, Khon Kaen University , Khon Kaen , Thailand.
Expert Review of Molecular Diagnostics
|October 1, 2019
Summary
Cholangiocarcinoma (CCA) biomarkers are crucial for early detection and improved outcomes. This review explores -omics approaches for discovering new diagnostic and prognostic markers from various samples.
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background:
- Cholangiocarcinoma (CCA) is a biliary tract malignancy with low global incidence, but high rates in Southeast Asia, linked to liver fluke infection.
- Most CCA patients present with advanced disease, leading to poor prognosis due to a lack of early-stage biomarkers.
Purpose of the Study:
- To review the discovery of diagnostic and prognostic biomarkers for CCA using -omics approaches.
- To summarize the current state of molecular candidate discovery and their potential clinical utility.
Main Methods:
- Genomics
- Epigenomics
- Transcriptomics
- Proteomics
- Analysis of CCA tissues, serum, and bile samples.
Main Results:
- Various potential molecular biomarkers for CCA have been identified through -omics studies.
- Some candidates have shown promise as diagnostic markers, but require further validation.
Conclusions:
- While progress has been made in identifying CCA biomarkers, further research is needed to find specific, cost-effective, and easily implementable markers for routine diagnostics.
